Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIRAGO phase 1 trial of repeat oncolytic adenovirus immunotherapy in recurrent glioblastoma
NL-OMON61504Phase 1Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, single-arm trial in glioblastoma (GBM), sponsored by Erasmus MC. Primary endpoint: Primary endpoint(s). Planned start Oct 2026; status: not yet recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON61504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61504.